Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Argorna SARS-CoV-2 mRNA vaccine
- Development stage
- Unknown
- Lead developer
- Agna Biopharmaceutical
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Argorna SARS-CoV-2 mRNA vaccine (also known as ARG-001) is a lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) vaccine developed by Argorna (Chengdu) Biotechnology for the prevention of COVID-19. The vaccine is designed to deliver mRNA encoding the spike (S) protein of the SARS-CoV-2 virus into host cells. Once administered, the host's cellular machinery translates the mRNA into the viral spike protein, which then acts as an antigen to stimulate the production of neutralizing antibodies and activate T-cell-mediated immune responses. This technology aims to provide protective immunity against infection and severe disease caused by SARS-CoV-2. As of 2022, the vaccine was undergoing Phase II clinical evaluation in China to assess its safety, tolerability, and immunogenicity in healthy adult populations.
- Other names
- Novel coronavirus mRNA vaccine (Argorna)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Argorna SARS-CoV-2 mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Argorna SARS-CoV-2 mRNA vaccine.